Post merger Astex ends SuperGen epigenetic deal with GSK
17 January 2012
Pial Ganguli
Please Login to read the full article.
17 January 2012
Pial Ganguli
Please Login to read the full article.
RELATED CONTENT
NEWS
- Merck Serono follows up F-Star investment with deal worth €492 million
- Aveo licences preclinical RON-targeted antibodies to J&J, for $15 million up front
- Anacor, GSK revise R&D pact on boron-containing anti-infective drug candidates
- Epigenetics-focused Epizyme gains $90M upfront in deal with Celgene on targeted cancer therapies
ANALYSIS
Other Informa Analysis
FEATURES
- Merck BioVentures: where biosimilars make a difference
- Piramal: regulatory overhaul would help India tackle disease challenges
EVENTS
Today
Continental Zara Hotel, Budapest, Hungary
Today
Radisson Blu Royal Hotel, Dublin
Today
Hotel Sofitel Hamburg Alter Wall
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
